Genetic deletion or pharmacologic inhibition of CXCR4 in T-ALL cells prolonged mouse survival and reduced T-ALL infiltration into the CNS, thus demonstrating the potential efficacy of targeting CXCR4 in combination with conventional chemotherapies135. The gene discussed is CXCR4; the disease is acute lymphoblastic leukemia.